Article | Open | Published:

The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand

Abstract

Schistosomiasis is a debilitating tropical disease caused by infection with parasitic blood flukes. Approximately 260 million people are infected worldwide, underscoring the clinical and socioeconomic impact of this chronic infection. Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mainstay for over three decades of clinical use. However, the molecular target(s) of PZQ remain undefined. Here we identify a molecular target for the antischistosomal eutomer — (R)-PZQ — which functions as a partial agonist of the human serotoninergic 5HT2B receptor. (R)-PZQ modulation of serotoninergic signaling occurs over a concentration range sufficient to regulate vascular tone of the mesenteric blood vessels where the adult parasites reside within their host. These data establish (R)-PZQ as a G-protein-coupled receptor ligand and suggest that the efficacy of this clinically important anthelmintic is supported by a broad, cross species polypharmacology with PZQ modulating signaling events in both host and parasite.

Introduction

Hundreds of millions of people are infected with parasitic worms1. One of the most burdensome infections is the neglected tropical disease schistosomiasis (Bilharzia) caused by parasitic flatworms of the genus Schistosoma 2. Schistosoma infections result from contact with fresh water containing cercariae, the free-swimming larval stage of the parasite. Cercariae penetrate the host’s skin, and then transform and mature into sexualized forms while undergoing a remarkable intravascular migration to defined vascular beds, where paired male and female worms complete their maturation and commence egg laying2,3. The debilitating impact of schistosomiasis results from the host’s immune response to schistosome eggs, deposited in prolific numbers in the liver, intestine and/or bladder where they elicit granulomatous inflammation, periportal fibrosis and hypertension2. Clinical outcomes span gastrointestinal and liver pathologies, genitourinary disease, anemia, malnutrition, and a heightened risk for comorbidities and HIV transmission. The associated disease burden encumbers third world economies with an annual loss of up to 70 million disability-adjusted life years4,5. Effective drug therapy for schistosomiasis is therefore a key healthcare priority.

Praziquantel, a tetracyclic tetrahydroisoquinoline derivative administered as a racemic mixture ((±)-PZQ), is the main drug therapy for combating schistosomiasis. PZQ causes rapid paralysis of schistosome musculature and subsequent tegumental damage that promotes immunological clearance of worms from the host. The World Health Organization estimates a considerable future demand for PZQ of 2 billion tablets over 5 years to support mass drug administration initiatives5. Clearly, the continued efficacy of PZQ is essential for this strategy and reports of PZQ-resistant worm isolates in both laboratory and field highlight an urgency in resolving how PZQ works6,7,8. Such knowledge would catalyze the development of next generation anthelmintics. Here we employ a variety of experimental approaches to demonstrate that the antischistosomal eutomer (R)-PZQ acts as a partial agonist of the human 5-HT2B receptor, establishing (R)-PZQ as a GPCR ligand. These data will prioritize future screening of flatworm GPCRs for a (R)-PZQ target and underscore an activity of (R)-PZQ on 5-HT2BR signaling in the human host, manifest within the vascular beds where the adult parasites reside.

Results

Mammalian GPCR target(s) of PZQ

Prior work has demonstrated an ergomimetic like action of PZQ to engage flatworm bioaminergic signaling pathways9. Specifically, PZQ exposure caused a bipolar regeneration phenotype in regenerating free-living planarian flatworms that was phenocopied by ergot alkaloids acting as serotonergic antagonists, but opposed by 5-hydroxytryptamine (5-HT9). Similarly, in both adult schistosome worms (Supplementary Fig. 1) and schistosomules9, PZQ evoked a rapid paralysis counteracted by exogenous 5-HT. On the basis of these observations, we considered whether PZQ acts as a direct serotoninergic ligand to oppose 5-HT evoked G-protein-coupled receptor (GPCR) signaling.

To investigate the possibility that PZQ engages serotoninergic GPCRs, in silico docking approaches were first applied. The resolved PZQ enantiomers—(R)-PZQ (the active, antischistocidal eutomer, Fig. 1a) and (S)-PZQ (Fig. 1b)—were screened against a panel of 3436 computational models, representing 1465 protein targets mostly of human origin, (‘MolScreen’). Both ligands were docked and scored into ensemble 4D10 models of various targets assembled in the Pocketome database11. The top candidate from the docking to pocket classification (‘dpc’ models) was the human 5-HT2B receptor (5-HT2BR), with (R)-PZQ possessing the highest predicted affinity (Supplementary Table 1). Figure 1c depicts the orientation of both (R)-PZQ and (S)-PZQ within the 5-HT2BR orthosteric binding pocket from modeling simulations. Different binding orientations for both PZQ enantiomers were predicted with the (R)-isomer exhibiting a more favorable hydrogen bond with the backbone amine group of L209 in extracellular loop 2 of 5-HT2BR (Fig. 1c).

Fig. 1
figure1

Resolution of stereoselective (R)-PZQ interaction with human 5-HT2BR. Structures of the PZQ enantiomers: active, a antischistocidal (R)-PZQ (top, red) and b (S)-PZQ (bottom, blue). c Docking poses of R-PZQ (light red) and S-PZQ (light blue) in the human 5HT2BR. Both isomers of PZQ dock favorably within the orthosteric pocket of the 5HT2BR crystal structure (Protein Databank Code: 5TVN). The R-isomer shows a better predicted binding score by 0.6 kcal/mole partially due to a more favorable hydrogen bond with the backbone NH group of L209. d Displacement of 3H-LSD binding at human 5-HT2BR by racemic PZQ ((±)-PZQ 10 µM, purple), (R)-PZQ (5 µM, red) and (S)-PZQ (5 µM, blue) in the PDSP primary screen (n = 5 for all measurements). e Complete binding displacement curves for 3H-LSD displacement at human 5-HT2BR for SB206553 (black) and (±)-PZQ (purple, n = 5 for both ligands). f Functional Assays. Ca2+ flux assays showing responses from fluo-4 loaded Flp-In T-REx cells stably expressing 5-HT2AR, 5-HT2BR, or 5-HT2CR at indicated concentrations of (±)-PZQ (purple, top), (R)-PZQ (red, middle) and (S)-PZQ (blue, bottom; n = 3 for each concentration) in cells expressing 5-HT2AR, 5-HT2BR, or 5-HT2CR

With these in silico predictions in hand, we profiled a broad panel of human GPCRs through the NIMH Psychoactive Drug Screening Program (PDSP12) first using racemic (±)-PZQ (10 µM) and then the resolved enantiomers ((R)-PZQ and (S)-PZQ13; Supplementary Fig. 2). (±)-PZQ exhibited a polypharmacological profile (Supplementary Fig. 3) consistent with predictions from the in silico modeling data (Fig. 1b). The ability of PZQ to engage host GPCRs likely explains prior reports of (±)-PZQ action on heart and smooth muscle14,15, and potentially other known activities of PZQ such as the bitterness of (S)-PZQ16, a taste transduced through GPCR signaling. This screen was then repeated using the individual enantiomers with the criterion for a positive screening hit defined as stereoselective inhibition of radioligand binding by (R)-PZQ, but not (S)-PZQ. This was observed at only one GPCR in the primary screen—the human 5-HT2B receptor (5-HT2BR)—where inhibition seen with (±)-PZQ was attributable solely to (R)-PZQ (Fig. 1d, Supplementary Fig. 3). These data support the in silico modeling, although demonstrate more biological selectivity for (R)-PZQ over (S)-PZQ at 5-HT2BR.

PZQ interaction with 5-HT2BR was then validated using radioligand binding and functional assays. Analysis of [3H]-LSD displacement by (±)-PZQ revealed complete displacement of specific [3H]-LSD binding at 5-HT2BR by unlabeled (±)-PZQ (K i = 5.3 µM, Fig. 1e). For functional activity, Ca2+ flux assays were performed in HEK293 cells expressing individual 5HT2R isoforms. (R)-PZQ evoked Ca2+ release in 5-HT2BR expressing cells at concentrations >1 µM (Fig. 1f). The peak amplitude of (R)-PZQ-evoked Ca2+ release was consistently less than evoked by 5-HT (Fig. 1d), suggesting action as a 5-HT2BR partial agonist. No Ca2+ release activity was observed using (S)-PZQ over a comparable concentration range (Fig. 1f). No Ca2+ release activity was observed in uninduced cells lacking 5-HT2BR expression, or cells expressing either 5-HT2AR or 5-HT2CR (Fig. 1f), indicating that (R)-PZQ activity was specific and selective for the 5-HT2BR. At other tested GPCRs, including several predicted by the modeling simulations (Supplementary Table 1), (±)-PZQ lacked Ca2+ release activity (Supplementary Fig. 4).

Further characterization of PZQ-evoked Ca2+ release was performed in a 5-HT2BR inducible cell line by confocal imaging. Neither (±)-PZQ, nor 5-HT, evoked cellular Ca2+ transients in the absence of 5-HT2BR induction, whereas acetylcholine (ACh) elevated cytoplasmic Ca2+ through endogenous GPCRs (Fig. 2a, b). Following 5-HT2BR induction, both (±)-PZQ and 5-HT triggered Ca2+ signals (Fig. 2a, b). Prior incubation of induced cells with serotonergic blockers ritanserin, SB2047471, or mesulergine blocked PZQ and 5-HT evoked Ca2+ transients, but failed to impact ACh-evoked Ca2+ signals (Fig. 2c). Dose-response relationships revealed (±)-PZQ activity over the micromolar range (EC50 = 8.1 µM; Fig. 2d) with Ca2+ release activity solely caused by the (R)-enantiomer (Fig. 2e, f). The 5-HT2BR blocker LY272015 also inhibited PZQ-evoked Ca2+ signals (Supplementary Fig. 5).

Fig. 2
figure2

(R)-PZQ triggers Ca2+ release via 5-HT2BR. a Representative fluorescence traces from a single experiment where single cells loaded with fluo-4-AM in a HEK293 cell line prior to (top), or after (bottom) 5-HT2BR induction. Traces show fluorescence ratio following addition of indicated ligands (final concentrations (±)-PZQ (75 µM), 5-HT (100 nM) or ACh (100 µM)), or vehicle (DMSO, 0.05%). b Pseudocolored confocal images are displayed from the indicated times (‘1’–‘4’) on associated fluorescence traces as introduced in Fig. 1a. Scalebar, 80 µm. c Peak fluorescence ratio (F/F0, where ‘F’ represents fluorescence at peak and ‘F0‘ represents fluorescence at time = 0) from cumulative Ca2+ imaging after addition of vehicle, (±)-PZQ, 5-HT or ACh in uninduced (open bars) or induced cell lines (solid, hatched bars; n ≥ 3 independent inductions). Serotonergic antagonists (ritanserin (100 nM, final concentration), SB204741 (100 nM), or mesulergine (200 nM) were preincubated with induced cells prior to addition of (±)-PZQ (75 µM), 5-HT (10 nM), or ACh (100 µM). Data represent means ± s.e.m. of peak responses averaged from multiple cells (>20) from n ≥ 3 independent inductions. d Dose-response relationship for (±)-PZQ efficacy in cells induced for 5-HT2BR expression (n = 6 for each concentration). e Confocal Ca2+ imaging assays with (±)-PZQ and resolved enantiomers in uninduced (top row) and 5-HT2BR induced cell lines (bottom three rows). Experiments were performed with racemic PZQ ((±)-PZQ), and individual (S)-PZQ and (R)-PZQ stereoisomers (5 µM, final concentration). Scalebar, 80 µm. f Processed data set from experiments such as shown in e representing population mean ± s.e.m. (>20 cells) from n ≥ 3 independent inductions

Next, we examined PZQ-evoked signaling using a transcriptional reporter assay, designed to monitor Ca2+-dependent NFAT translocation (Supplementary Fig. 6A). In HEK293 cells expressing the reporter construct alone, neither (±)-PZQ nor 5-HT increased the basal luminescence signal (Supplementary Fig. 6B). In cells transiently transfected with 5-HT2BR, both PZQ and 5-HT elicited NFAT translocation and this response was blocked by ritanserin (Supplementary Fig. 6B). (R)-PZQ activation of NFAT occurred over the micromolar range (Supplementary Fig. 6C), again less potent and penetrant than observed with 5-HT (Figs. 1d, 2d). Therefore, multiple experimental approaches demonstrated (R)-PZQ acted as a partial agonist at human 5-HT2BR.

Action of (R)-PZQ at host GPCRs

These data are significant for two reasons. First they identify PZQ as a bona fide GPCR ligand at a defined molecular target. This discovery prioritizes future screening of flatworm GPCRs (~120 GPCRs in schistosomes17) for a receptor selectively engaged by (R)-PZQ that could be a key target for future antischistosomal drug development18,19. Second, these data suggest PZQ—conventionally viewed as a selective antiparasitic therapy—can interact with endogenous 5-HT2BRs in the human host. One pathophysiologically relevant effect would be an activity of (R)-PZQ on host mesenteric vascular beds, a destination of the mature, paired adult S. mansoni and S. japonicum blood flukes and sites where egg laying commences2,3 (Fig. 3a). After drug treatment, worms are rapidly displaced from their mesenteric habitat to the liver where elimination occurs. This ‘hepatic shift’ is a frequently used assay for drug efficacy and has been attributed to loss of worm muscle tone evoked by antischistosomal agents20,21 as seen in vitro (Supplementary Movie 1). Serotonergic ligands are well known regulators of the tone of arteries and veins22,23, including mesenteric vessels23, such that PZQ-evoked changes in mesenteric blood flow may help ‘flush’ PZQ-paralyzed worms toward the liver. Levels of PZQ within the splanchnic vasculature likely reach levels an order of magnitude higher than peak plasma concentrations that are measured after first-pass metabolism of the drug (>4 µM for 40 mg/kg human dosing, even higher in mouse models24,25). Therefore, PZQ concentration within mesenteric vessels falls well within the concentration range for causing host serotonergic effects demonstrated in vitro (Figs. 1, 2).

Fig. 3
figure3

(R)-PZQ constricts mouse mesenteric vasculature. a Image of mesentery surrounding mouse intestine, showing blood vessel containing a schistosome worm-pair (inset). b Representative image of a surgically isolated piece of mouse mesenteric artery held under tension between two clamped wires. Scalebar, 1 mm. c Changes in tension triggered by varied manipulations. Left, sustained contraction of vessels in KPSS and 5-HT (10 µM). Right, tension in individual arteries incubated in the presence of vehicle (DMSO, open circle) or SB204741 (10 µM, closed circle), and challenged with (R)-PZQ (50 µM) or (S)-PZQ (50 µM). W, wash; complete media exchange. Preincubation of strips with SB204741 (10 µM) attenuated (R)-PZQ evoked vasoconstriction. d Cumulative data set from experiments reporting effects of ligands relative to KPS(S)-evoked contractile tension, concentrations of ligands: 5-HT (1 µM), (R)-PZQ (50 µM), (S)-PZQ (50 µM), SB204741 (10 µM). Replicate number for each measurement as indicated, where individual measurements reflect the response from a naïve artery isolated from different mice. Data are presented as mean ± s.d. Probability, p < 0.05 (*), p < 0.01 (**). e Schematic model (not to scale) depicting (R)-PZQ action on both parasite (contraction) and host vasculature (contraction, increased perfusion pressure) facilitating hepatic shift of worms

The activity of PZQ within the mesenteric vasculature of uninfected mice was assessed by measuring mesenteric artery tone using wire myography. Mounted vessel segments (Fig. 3b) exhibited a rapid, sustained contraction to high K+ media which reversed upon media exchange (Fig. 3c). Addition of 5-HT to resting vessel segments also elicited a protracted, contractile response that declined over time (Fig. 3c). Addition of (R)-PZQ to naive vessels mimicked the profile of 5-HT evoked contractions (Fig. 3c), and this effect was prevented by preincubation with SB204741, a 5-HT2BR antagonist (Fig. 3c). No changes in resting tone were observed with (S)-PZQ. PZQ also evoked contraction of hepatic portal vein segments (Supplementary Fig. 7), again mimicking 5-HT action26. The cumulative data set demonstrates (R)-PZQ caused mesenteric artery vasoconstriction, mimicking the action of 5-HT (Fig. 3d).

In conclusion, we demonstrate that PZQ is a GPCR ligand, with antischistocidal (R)-PZQ acting as a low micromolar affinity partial agonist at human 5-HT2B receptors. Activity at both parasite and host receptors—both targets potentially being GPCRs—likely contributes to clinical efficacy of PZQ by combining a deleterious paralytic effect on the parasite (Supplementary Movie 1) with beneficial host effects that promote worm clearance. We propose PZQ causes contraction of both the parasite and host mesenteric vessels to increase perfusion pressure and flush paralyzed worms to the liver (Fig. 3e). PZQ activity at host 5-HT2BRs may be further enhanced in individuals infected with chronic schistosomiasis where pathological changes slow drug elimination24, heighten serotonergic sensitivity26 and lower basal arteriolar resistance27. Further, the beneficial effects of host GPCR engagement may extend beyond the vasculature given a role for 5HT2BRs in regulating inflammation, liver fibrosis and regeneration: all outcomes relevant to chronic schistosomiasis pathology28,29. In conclusion, these data support a strategy for developing novel anthelmintics with cross species polypharmacology to reinforce disease mitigating actions in both host and parasite.

Methods

Reagents

Ritanserin, SB204741 and mesulergine were from Tocris Bioscience. All other ligands were from Sigma-Aldrich. Cell culture reagents were from Invitrogen. PZQ enantiomers ((R)-[-]PZQ and (S)-[+]PZQ) were resolved (Supplementary Fig. 2) using methods published by Woelfle et al.13.


Mammalian GPCR profiling

PZQ (racemic and enantiomers) were screened against human GPCRs using primary and secondary assays coordinated through the NIMH Psychoactive Drug Screening Program (PDSP). Full details describing these methods are available in the PDSP Assay Protocol Book available online (https://pdspdb.unc.edu/pdspWeb/). PZQ was dissolved in 100% ethanol at a concentration of 100 mM to achieve a maximal assay concentration (up to 100 µM) for both binding and functional assays. Ca2+ flux experiments utilized tetracycline-inducible stable cell lines for 5HT2A, 5HT2B, and 5HT2C receptors initially generated using the Flp-In 293 T-REx tetracycline inducible system30 (a gift from the Roth Lab, Invitrogen). Cells were maintained in DMEM (ThermoFisher, 10569010) supplemented with 10% dialyzed fetal bovine serum (Gibco, 26400044), 50 U/mL Penicillin-Streptomycin (ThermoFisher Scientific, 15140122), 10 µg/ml Blasticidin (Research Products International, B12150-0.1) and 100 µg/ml Hygromycin B (ThermoFisher Scientific, 10687010) at 37 °C and 5% CO2. For Ca2+ flux assays, receptor expression was induced with 2 µg/mL tetracycline, and cells were plated into white 384 clear bottom, tissue culture plates in 40 μL of DMEM containing 1% dialyzed FBS at a density of ~15,000 cells per well the day before the assay. Next day, media was decanted and 20 µL per well of Fluo-4 Direct dye (Invitrogen) was added and incubated for 1 h at 37 °C. The cells were stimulated with test compounds diluted in drug buffer (HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) and calcium flux was measured using a FLIPRTETRA (Molecular Devices). Plates were read for fluorescence initially for 10 s (1 read per second) to establish a baseline, and then stimulated with drug dilutions or buffer and read for an additional 110 s. Peak fluorescence in each well was normalized to maximum-fold increase over baseline. The data were normalized to maximum peak fold over basal fluorescence by 5-HT (100%) and baseline fluorescence (0%). The data were analyzed using the sigmoidal dose-response function built into GraphPad Prism 5.0.


In silico modeling

(R)-PZQ and (S)-PZQ were screened against a panel of 3436 computational models designed to predict activities of arbitrary chemical compounds, representing 1465 proteins targets mostly of human origin (so called ‘MolScreen’ panel). The earlier version of this set of models that included different classes of targets31 described and validated the panel. Two main types of three dimensional docking models were used: ‘dpc’ models (349 models representing the conformational ensembles of binding pocket conformations from the Pocketome database11) and ‘dfa’ models (pharmacophoric field models based on the continuous three dimensional pharmacophoric fields of the diverse co-crystallized ligands from the Pocketome database, enhanced by training on the activity data from the ChEmbl database32,33).


Confocal Ca2+ imaging

For single-cell confocal Ca2+ imaging, the 5HT2B inducible cell line was seeded onto collagen-coated, 35 mm glass bottom dishes (MatTek, P35GCOL-0-14-C) at a density of 1 × 104 cells three days prior to imaging. Two days prior to imaging, 5-HT receptor expression was induced by supplementing the growth media with 1 µg/ml doxycycline (Sigma-Aldrich, D3447). Two hours prior to conducting experiments, growth medium was exchanged for EMEM supplemented with 1% dialyzed FBS, plus antibiotics. The cells were washed twice with Hank’s balanced salt solution (HBSS), and incubated with Fluo-4-AM (4 µM) and Pluronic F127 (0.4%) for 25 minutes at room temperature. The cells were then washed twice with HBSS, and left at room temperature (30 min) for de-esterification. Dishes were mounted on an Olympus IX81 microscope and fluorescence changes (λ ex = 488 nM, (λ em = 513 ± 15 nm bandpass) monitored using a Yogokawa spinning disk confocal (CSU-X-M1N) and an Andor iXon Ultra 888 EMCCD camera. HEK293 cell lines were sourced from ATCC (CRL-1573) and found to be negative for mycoplasma contamination.


Wire myography

Swiss Webster mice (female, aged 10–13 weeks) were obtained from Charles River Laboratories. Measurements of mouse mesenteric vessel tone were made using a multimyograph system (DMT, Aarhus, Denmark). Vessel strips were isolated from second order mesenteries and equilibrated for ≥30 min in gassed (95% O2, 5% CO2), physiological saline solution (PSS, 130 mM NaCl, 4.7 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM dextrose, 0.026 mM EDTA, 1.6 mM CaCl2, pH 7.4 at 37 °C). To identify the optimal pre-stretch value for experiments, a normalization factor (IC1/IC100) was calculated for individual test strips34,35, defined as the ratio of the internal circumference at which the maximum response to vasoconstriction (KCl, plus 40 µM norepinephrine) was observed (IC1), divided by the internal circumference at which a transmural wall pressure of 100 mm of Hg is attained on a length-tension plot overlayed with a La Place transformation isobar (IC100). After vessel equilibration, reactivity was measured under isometric conditions in response to KCl (KPSS, 74.7 mM NaCl, 60 mM KCl, 1.18 mM KH2PO4, 1.17 mM MgSO4, 14.9 mM NaHCO3, 5.5 mM dextrose, 0.026 mM EDTA, 1.6 mM CaCl2, pH 7.4 at 37 °C) or indicated ligands, as per published protocols. All animal experiments followed ethical regulations approved by the University of Minnesota IACUC committee and reviewed by the National Institutes of Health (NIAID).


Adult Schistosoma mansoni mobility assays

Infected mice were provided by the Biomedical Research Institute (33) from which adult worms were collected by portal perfusion 6–8-week-post infection. Mobility experiments were conducted 24–48 h after worm collection using a compound microscope equipped with a digital video camera to acquire video recordings (3 frames per second for 1–2 min) of worms exposed to various drugs. Analysis was performed in ImageJ after file import using the Bio-Formats plugin. Differences in illumination were corrected using the stack deflicker function of the wrMTrck plugin. Images were processed by converting to binary format, and mobility was assayed by measuring the average difference in pixels resulting from subtracting two consecutive frames, providing a measurement of the worms displacement over that period (~0.3 s). This calculation was performed for each frame in the video, and the results were averaged over the length of the recording to provide a metric of worm movement. Unless otherwise noted, values reported represent the mean ± standard error of at least three independent experiments.


Mammalian GPCR profiling

Primary GPCR screening assays were coordinated through the NIMH Psychoactive Drug Screening Program (PDSP). Methods and statistical analyzes for radioligand binding and functional assays are available in the PDSP Assay Protocol Book available online (https://pdspdb.unc.edu/pdspWeb/). Ca2+ flux assays were performed as similarly described, except experiments utilized muscarinic M1, M3, M5 receptors stably expressed in CHO cells. For experiments measuring cAMP, experiments utilized co-transfection with the cAMP split-luciferase reporter GloSenso(R)-22F plasmid (Promega, 1:1 ratio with receptor) and were read for luminescence on a TriLux Microbeta (Perkin Elmer). For Gi/o mediated cAMP inhibition, forskolin (1 µM) was used to stimulate cAMP via adenylyl cyclase activation.


NFAT reporter assay

The Ca2+ sensitive transcriptional luciferase reporter pGL4.30[luc2P/NFAT-RE/Hygro] (Promega, E8481) was transiently transfected into the 5HT2BR stable cell line. Briefly, 3 × 106 cells were plated in a Nunc Cell Culture Treated flask (25 cm2, ThermoFisher) and transfected with lipofectamine 2000 (ThermoFisher) plus 1 µg of plasmid DNA according to the manufacturer’s protocol. The following day, culture media was replaced with induction media (DMEM + 10% dialyzed FBS supplemented with 1 µg/ml doxycycline), and 24 h later cells were re-plated into 96 well, solid white plates (Costar, 3917). After allowing 3 h for cells to adhere, drugs were added at 20× concentration. For antagonist experiments, cells were incubated with 5HT2B R antagonists for 2 h prior to subsequent addition of agonist. After 18 h culture in the presence of agonist, plates were assayed using the ONE-Glo Luciferase Assay System (Promega, E6120) and read on a GloMax-Multi Detection System plate reader (Promega).


Statistical analysis

Except for the myography experiments, data (PDSP data, confocal calcium imaging) were analyzed using the two tailed Student’s t-test, and are reported except where explicitly indicated as mean ± s.e.m for independent biological replicates (defined as independent transfections or inductions). For myography experiments, where the amounts of resolved enantiomers were limiting, measurements were made in vessels isolated from 3–6 mice, a sample size providing a α-significance criterion of 0.05 and a β of 0.9. No randomization or blinding was used in the animal studies, as no comparative analyzes were involved. The statistical significance between experimental groups in myography experiments was determined using the Mann–Whitney test and data are presented as mean ± s.d. for these assays. Replicate numbers for individual experiments are outlined within Figure Legends or Figures as appropriate for clarity. Probability values of p < 0.05 were considered statistically significant.


Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Data Files or from the corresponding author on reasonable request.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.

    Hotez, P. J. et al. Helminth infections: the great neglected tropical diseases. J. Clin. Invest. 118, 1311–1321 (2008).

  2. 2.

    Ross, A. G. P. et al. Schistosomiasis. NEJM 346, 1212–1220 (2002).

  3. 3.

    Wilson, R. A. & Coulson, P. S. Schistosoma mansoni: dynamics of migration through the vascular system of the mouse. Parasitology 92, 83–100 (1986).

  4. 4.

    Hotez, P. J. & Fenwick, A. Schistosomiasis in Africa: an emerging tragedy in our new global health decade. PLoS Negl. Trop. Dis. 3, e485 (2009).

  5. 5.

    Hotez, P. J., Engels, D., Fenwick, A. & Savioli, L. Africa is desperate for praziquantel. Lancet 376, 496–498 (2010).

  6. 6.

    Doenhoff, M. J. et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136, 1825–1835 (2009).

  7. 7.

    Melman, S. D. et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis. 3, e504 (2009).

  8. 8.

    Bergquist, R., Utzinger, J. & Keiser, J. Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? Infect. Dis. Poverty 6, 74 (2017).

  9. 9.

    Chan, J. D. et al. Ergot alkaloids (Re)generate new leads as antiparasitics. PLoS Negl. Trop. Dis. 9, e0004063 (2015).

  10. 10.

    Bottegoni, G., Kufareva, I., Totrov, M. & Abagyan, R. Four-dimensional docking: a fast and accurate account of discrete receptor flexibility in ligand docking. J. Med. Chem. 52, 397–406 (2009).

  11. 11.

    Kufareva, I., Ilatovskiy, A. V. & Abagyan, R. Pocketome: an encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Res. 40, D535–540 (2012).

  12. 12.

    Roth, B. L. et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc. Natl Acad. Sci. USA 99, 11934–11939 (2002).

  13. 13.

    Woelfle, M. et al. Resolution of praziquantel. PLoS Negl. Trop. Dis. 5, e1260 (2011).

  14. 14.

    Chubb, J. M., Bennett, J. L., Akera, T. & Brody, T. M. Effects of praziquantel, a new anthelmintic, on electromechanical properties of isolated rat atria. J. Pharmacol. Exp. Ther. 207, 284–293 (1978).

  15. 15.

    Jim, K. & Triggle, D. J. Actions of praziquantel and 1-methyladenine in guinea-Pig Ileal longitudinal muscle. Can. J. Physiol. Pharmacol. 57, 1460–1462 (1979).

  16. 16.

    Meyer, T. et al. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl. Trop. Dis. 3, e357 (2009).

  17. 17.

    Zamanian, M. et al. The repertoire of G protein-coupled receptors in the human parasite Schistosoma mansoni and the model organism Schmidtea mediterranea. BMC Genom. 12, 596 (2011).

  18. 18.

    Chan, J. D. et al. A miniaturized screen of a Schistosoma mansoni serotonergic G protein-coupled receptor identifies novel classes of parasite-selective inhibitors. PLoS Pathog. 12, e1005651 (2016).

  19. 19.

    Angelucci, F. et al. The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology 134, 1215–1221 (2007).

  20. 20.

    Meister, I. et al. Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob. Agents Chemother. 58, 5466–5472 (2014).

  21. 21.

    Buttle, G. A. & Khayyal, M. T. Rapid hepatic shift of worms in mice infected with Schistosoma mansoni after a single injection of tartar emetic. Nature 194, 780–781 (1962).

  22. 22.

    Vanhoutte, P. M. Serotonin and the vascular wall. Int. J. Cardiol. 14, 189–203 (1987).

  23. 23.

    Watts, S. W., Morrison, S. F., Davis, R. P. & Barman, S. M. Serotonin and blood pressure regulation. Pharmacol. Rev. 64, 359–388 (2012).

  24. 24.

    Olliaro, P., Delgado-Romero, P. & Keiser, J. The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J. Antimicrob. Chemother. 69, 863–870 (2014).

  25. 25.

    Botros, S. S., El-Din, S. H., El-Lakkany, N. M., Sabra, A. N. & Ebeid, F. A. Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities. J. Parasitol. 92, 1344–1349 (2006).

  26. 26.

    Silva, C. L., Morel, N., Lenzi, H. L. & Noel, F. Increased reactivity to 5-hydroxytryptamine of portal veins from mice infected with Schistosoma mansoni. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 120, 417–423 (1998).

  27. 27.

    Sarin, S. K., Mosca, P., Sabba, C. & Groszmann, R. J. Hyperdynamic circulation in a chronic murine schistosomiasis model of portal hypertension. Hepatology 13, 581–584 (1991).

  28. 28.

    Ebrahimkhani, M. R. et al. Stimulating healthy tissue regeneration by targeting the 5-HT(2)B receptor in chronic liver disease. Nat. Med. 17, 1668–1673 (2011).

  29. 29.

    Anthony, B., Allen, J. T., Li, Y. S. & McManus, D. P. Hepatic stellate cells and parasite-induced liver fibrosis. Parasites Vectors 3, 60 (2010).

  30. 30.

    Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389 (2017). e312.

  31. 31.

    Chen, Y. C., Totrov, M. & Abagyan, R. Docking to multiple pockets or ligand fields for screening, activity prediction and scaffold hopping. Future Med. Chem. 6, 1741–1755 (2014).

  32. 32.

    Totrov, M. Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR. Chem. Biol. Drug Des. 71, 15–27 (2008).

  33. 33.

    Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017).

  34. 34.

    Halpern, W. & Mulvany, M. J. Tension responses to small length changes of vascular smooth muscle cells [proceedings]. J. Physiol. 265, 21P–23P (1977).

  35. 35.

    Warshaw, D. M., Mulvany, M. J. & Halpern, W. Mechanical and morphological properties of arterial resistance vessels in young and old spontaneously hypertensive rats. Circ. Res. 45, 250–259 (1979).

Download references

Acknowledgements

Schistosome-infected mice were provided by the NIAID Schistosomiasis Resource Center at the Biomedical Research Institute (Rockville, MD) through NIH-NIAID Contract HHSN272201000005I for distribution through BEI Resources. Work was supported by the NIH (GM088790, R21AI25821, R21AI130642 to J.S.M.; RO1MH61887 to J.D.M. and B.L.R.; R01AI087807 to C.C., T.R.W. and P.M.C.), NSF (MCB1615538 to J.S.M.) and the National Institute of Mental Health’s Psychoactive Drug Screening Program PDSP screening program, contract #HHSN-271-2013-00017-C (NIMH PDSP). We thank Joyce Lee, Nawal Yahya and Jonathan Wojcik for their assistance preparing this work.

Author information

J.D.C, P.M.C., G.S.G., and J.D.M. performed experiments, analyzed data and contributed figures for the manuscript. K.S., T.R.W., P.I.D. performed chemical isolation and validated purity of PZQ enantiomers. Y.Y and R.A. performed in silico modeling analyzes. B.L.R., R.A., C.C., and J.S.M established hypothesis and supervised experimental studies. J.D.C. and J.S.M. co-wrote the manuscript with help from other authors.

Competing interests

The authors declare no competing financial interests.

Correspondence to Jonathan S. Marchant.

Electronic supplementary material

  1. Supplementary Information

  2. Description of Additional Supplementary Files

  3. Supplementary Movie 1

Rights and permissions

Creative Commons BY

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

  • Unexplored therapeutic opportunities in the human genome

    • Tudor I. Oprea
    • , Cristian G. Bologa
    • , Søren Brunak
    • , Allen Campbell
    • , Gregory N. Gan
    • , Anna Gaulton
    • , Shawn M. Gomez
    • , Rajarshi Guha
    • , Anne Hersey
    • , Jayme Holmes
    • , Ajit Jadhav
    • , Lars Juhl Jensen
    • , Gary L. Johnson
    • , Anneli Karlson
    • , Andrew R. Leach
    • , Avi Ma'ayan
    • , Anna Malovannaya
    • , Subramani Mani
    • , Stephen L. Mathias
    • , Michael T. McManus
    • , Terrence F. Meehan
    • , Christian von Mering
    • , Daniel Muthas
    • , Dac-Trung Nguyen
    • , John P. Overington
    • , George Papadatos
    • , Jun Qin
    • , Christian Reich
    • , Bryan L. Roth
    • , Stephan C. Schürer
    • , Anton Simeonov
    • , Larry A. Sklar
    • , Noel Southall
    • , Susumu Tomita
    • , Ilinca Tudose
    • , Oleg Ursu
    • , Dušica Vidovic´
    • , Anna Waller
    • , David Westergaard
    • , Jeremy J. Yang
    •  & Gergely Zahoránszky-Köhalmi

    Nature Reviews Drug Discovery (2018)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.